Clinical Challenges in Breast Surgery: Triple Negative Breast Cancer
Aug 2, 2021
auto_awesome
The podcast discusses the multidisciplinary management of triple negative breast cancer. Topics covered include diagnostic workup, chemotherapy regimens and immunotherapy, surgical approaches and breast reconstruction, and surveillance and follow-up recommendations for patients.
Triple negative breast cancer is a subtype that lacks estrogen receptor, progesterone receptor, and HER2 receptor, and is more aggressive in younger women.
Patients with triple negative breast cancer typically receive neoadjuvant chemotherapy before surgery and may benefit from additional systemic treatments if residual disease is present.
Deep dives
Key Point 1: Evaluating a Breast Lump and Imaging Workup
When evaluating a patient with a new breast lump, it is important to assess the patient's baseline risk of developing breast cancer. This can be done by asking specific questions about the patient's medical history, family history, and risk factors. Imaging workup typically includes a breast ultrasound and, if the patient is over 30 years old, a diagnostic mammogram. The diagnostic workup helps to determine the characteristics of the breast lump and guide further evaluation.
Key Point 2: Triple Negative Breast Cancer
Triple negative breast cancer is a subtype of breast cancer that lacks the expression of the estrogen receptor, progesterone receptor, and HER2 receptor. It is more frequently diagnosed in younger women and tends to be more aggressive compared to other subtypes. Patients with triple negative breast cancer typically receive neoadjuvant chemotherapy, meaning chemotherapy before surgery. Treatment options for triple negative breast cancer are limited as endocrine therapy and HER2-targeted therapies are not effective. Genetic testing is also recommended for patients with triple negative breast cancer, as these tumors are commonly associated with BRCA gene mutations.
Key Point 3: Surgical Approach and Adjuvant Therapy
The surgical approach for a patient with triple negative breast cancer depends on various factors, including tumor size and patient preference. Options include lumpectomy (breast-conserving surgery) with radiation or mastectomy. The decision may involve discussions between the surgeon and the patient about the benefits and risks of each option. In terms of adjuvant therapy, patients with residual disease after neoadjuvant chemotherapy may benefit from additional systemic treatments, such as capecitabine, which has shown improved survival. Surveillance after treatment typically includes regular clinical breast exams, mammograms, and potentially breast MRI for certain individuals.
A young woman is referred urgently to your breast surgical oncology clinic for a second opinion. She has been told that she needs to have an urgent mastectomy for a palpable triple negative breast cancer with suspicious axillary lymphadenopathy. Are there other options she should consider? Join Drs. Michael Alvarado, Rita Mukhtar, and Alexa Glencer as they discuss the multidisciplinary management of a patient with triple negative breast cancer.
In this episode, we review the diagnosis and classification of triple negative breast cancer, its biologic implications, surgical management including the role of sentinel lymph node biopsy vs axillary dissection, and the role of targeted chemotherapy including the recent FDA approval of immunotherapy for triple negative breast cancer in the neoadjuvant setting and indication for adjuvant chemotherapy for patients with residual disease following neoadjuvant therapy.
Links: Enhanced recurrence and survival benefit of adjuvant chemotherapy for hormone receptor negative breast cancer compared to hormone receptor positive breast cancer
Berry et al (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA; 295(14): 1658-1667.
Neoadjuvant pembrolizumab for triple negative breast cancer
Schmid et al (2020). Pembrolizumab for early triple negative breast cancer. New England J of Medicine; 382(9): 810-821.
ACOSOG 1071: Sentinel lymph node biopsy for patients who received neoadjuvant chemotherapy
Boughey at al (2013). Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG 1071 (Alliance) clinical trial. JAMA; 310(14): 1455-1461.
Adjuvant capecitabine for triple negative breast cancer patients with residual disease following neoadjuvant chemotherapy:
Masuda et al (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England J of Medicine; 376(22): 2147-2159.